Background: Non-alcoholic fatty liver disease (NAFLD) is expected to become a
| INTRODUCTION
Hepatocellular carcinoma (HCC) has the second most rapidly rising cancer incidence in the United States with an estimated incidence of 6.2 to 7.4 per 1 00 000 persons.
1,2 Concurrently with its rising incidence, the rate of cancer-related mortality from HCC is the highest among reported cancers from 2003 to 2012. 2 The prognosis of HCC remains dismal as evident by its incidence-based mortality rate of 5 per 1 00 000 persons. 3 While the increasing rate of HCC incidence and mortality in the United States is predominantly a sequela of chronic hepatitis C (HCV) infection, non-alcoholic fatty liver disease (NAFLD) is expected to become one of the leading causes of HCC incidence and mortality in the United States based on an annual rate of NAFLD-HCC that has increased by approximately 10% in the last decade. [4] [5] [6] [7] Treatment with curative intent for HCC, including orthotopic liver transplantation (OLT), hepatic resection and radiofrequency ablation (RFA), has been shown to improve overall survival for early tumour stages. 1, [8] [9] [10] Patients who receive OLT, resection or RFA for HCC can achieve a 5-year survival of 50%-75%, 50%-93% or 33%-40%, respectively. 10 While treatment algorithms have provided guidance on the selection of appropriate candidates for curative treatments, preference for OLT, resection, or RFA remains debatable and largely contingent on the patient's clinical characteristics, liver function and tumour biology. [9] [10] [11] [12] [13] [14] [15] [16] Large studies to compare the three major types of curative treatments, and by HCC aetiology, have yet to be performed. 9 As NAFLD-related HCC is becoming an increasingly recognised disease, comparison data on survival after receipt of different curative therapies may help inform an appropriate first-line treatment approach. Data on survival after curative treatment among patients with NAFLD-related HCC remain limited to small sample sizes and heterogenous treatment groups that combine OLT, resection and RFA. [17] [18] [19] While patients with NAFLD-HCC have been reported to have lower overall survival compared with individuals with other HCC aetiologies, 6,17 this difference is not observed when restricted to those who receive curative treatment. [18] [19] [20] Comparison of survival by type of curative treatment among patients with NAFLD-HCC and between different HCC aetiologies may help delineate previously reported inconsistencies of overall survival among patients with NAFLD-HCC.
Our primary aim was to identify overall survival differences after receipt of curative treatment (OLT vs resection vs RFA) by NAFLD and non-NAFLD-HCC aetiologies including chronic hepatitis B (HBV), HCV and alcoholic liver disease (ALD). Secondary analyses aimed to determine clinical factors that predicted receipt of curative treatment and mortality after OLT, resection, or RFA.
| MATERIALS AND METHODS

| Study design and data source
A retrospective cohort study, composed of Medicare beneficiaries diagnosed with HCC between 1991 and 2011, was performed using 
| Statistical analyses
Descriptive statistics and comparative results were obtained using the chi-squared test, Student's t test and analysis of variance, as appropriate. Survival analysis was performed using the log-rank test and presented using the Kaplan-Meier method. Multivariate logistic regression models were constructed using covariates with P < .1 on univariate analysis. Odds ratios were presented to identify variables that associated with receipt of curative treatment. Cox's proportional hazard regression was used to identify independent predictors of mortality after receipt of curative treatment. Statistical significance was defined as a 2-tailed P < .05. Statistical analyses were performed using Stata 14 (Stata Corporation, College Station, TX).
3 | RESULTS
| Patient and tumour characteristics
The total cohort included 17 664 patients with confirmed diagnosis of HCC and underlying HCV (44.4%), NAFLD (33.4%), ALD (13.1%)
or HBV (9.1%). The cohort was predominantly male (72.4%) with a median age of 70 (21-106) years, Caucasian (64.5%), and enrolled in Medicare because of age (73.4%) vs disability and/or end-stage renal disease (Table 1) . While most patients had liver cirrhosis (65.8%), the majority did not have decompensated liver disease (58.6%). History of ischaemic heart disease and/or congestive heart failure, ischaemic stroke and chronic kidney disease were not prevalent in the total cohort (36.9%, 7.2% and 20.4%, respectively). Most tumours were localised (52.5%), and over half of primary tumours were small, defined as <5 cm in size (57.6%). Among HCC cases with available histologic grade, tumours were predominantly characterised as well-differentiated (14.6%) or moderately differentiated (16.3%).
Comparison of patient and tumour characteristics by HCC aetiology revealed that the NAFLD-HCC group had a significantly higher proportion of females (33%), history of cardiac disease (49%), and history of ischaemic stroke (10.2%) and a lower proportion of cirrhosis (43.6%) and decompensated liver disease (31.4%),
as compared with HCV, HBV and ALD aetiologies (P < .001). While the NAFLD group was older than the HCV, HBV and ALD groups, the age difference was not statistically significant (P = .15).
Although most tumours of NAFLD-related HCC were localised (48%), patients with NAFLD-HCC had comparatively more distant tumours than the HCV, HBV and ALD groups (14.1% vs 8.8%, 8.9% and 11.3%, respectively, P < .001). A larger proportion of primary NAFLD-HCC was >5 cm in diameter, as compared with other HCC aetiologies (57.1% vs 32% for HCV, 42.1% for ALD and 44.1% for HBV, P < .001). There was also a higher proportion of well-differentiated and moderately differentiated HCC in the NAFLD group (33.8%) vs HCV (29.6%), HBV (30.7%) and ALD (27.4%) (P < .001).
| Treatment characteristics
The vast majority of the overall HCC cohort failed to receive a form of curative treatment (85.2%). Only 6.9% received OLT, with NAFLD-related HCC having the lowest proportion of graft recipients (2.3% vs 10.5% for HCV, 7.6% for HBV and 5.8% for ALD, P < .001). Hepatic resection was also uncommon in the overall HCC cohort (4.9%), with HBV-related HCC having the most resections (13.6%) as compared with HCV (5.3%), NAFLD (3%) and ALD (2.6%), P < .001. RFA alone was performed in only 3% of the overall cohort, with NAFLD-HCC having the lowest proportion of aetiologies (1.6% vs HBV 4.7%, HCV 3.8% and ALD 2.8%, P < .001).
Among OLT recipients, the vast majority had HCV (67.9%) vs ALD, NAFLD and HBV (11.1%, 11.1% and 9.9%, respectively) ( 
| Survival by curative treatment for NAFLD-HCC
Patients in the NAFLD-HCC group had a median survival of 2.3 (0-12.9) years after any curative treatment. Overall median survival was the longest after OLT (3.2, 0-12.9 years), followed by resection (2.4, 0-12.0 years) and RFA (1.3, 0-6.9 years) (P < .001) (Figure 2A ). Among those who received RFA for HCC treatment, no difference in survival existed between those with and without cirrhosis (P = .07).
T A B L E 2 Baseline characteristics of the total cohort by curative treatment
Those with decompensated liver disease had worse survival after RFA as compared with those without history of decompensation: median 1 (0-4.7) years vs 1.8 (0-6.9) years, P = .001.
| Predictors of mortality after receipt of curative treatment
OLT recipients for HCC indication experienced a trend towards higher mortality if they were older or had cardiac disease, ischaemic stroke, cirrhosis, decompensated liver disease or larger tumour size >5 cm, although none were demonstrated to be statistically significant on multivariate analysis (Table 3 ). The only significant predictors of mortality among OLT recipients were CKD (HR 1.41, P = .002) and metastatic HCC (HR 1.29, P = .04). No significant predictors of mortality, including age, male sex, cardiovascular disease, decompensated liver disease, cirrhosis and tumour characteristics, were identified for patients with NAFLD-HCC after OLT.
Predictors of mortality after hepatic resection included cirrhosis (HR 1.34, P = .005), decompensated liver disease (HR 1.61, P < .001) and metastatic HCC (HR 1.69, P < .001) ( Table 4 ). Male sex, older age, cardiac disease, ischaemic stroke, CKD, NAFLD-HCC vs non-NAFLD-HCC, and primary tumour size >5 cm were not significantly associated with increased mortality after resection. Among those with NAFLD-HCC, male sex, cirrhosis and metastatic HCC were the only significant predictors of mortality after resection (1.54, P = .04, 1.83, P = .04, and 1.97, P = .01, respectively).
RFA recipients had an increased risk of mortality if they had decompensated liver disease (HR 1.54, P < .001) or metastatic HCC (HR 1.59, P = .001. Male sex, older age, cardiac disease, ischaemic stroke, CKD, cirrhosis, NAFLD-HCC and large tumour size were not associated with increased mortality after RFA. No significant predictors of mortality were identified for NAFLD-HCC after RFA.
| DISCUSSION
Our study provides large population-based findings on receipt of and overall survival after curative treatment among patients with NAFLD-vs non-NAFLD-related HCC. Using homogenous treatment groups, we were able to delineate inconsistencies in previously reported studies about post-treatment survival among patients with NAFLD-related HCC. [17] [18] [19] In summary, patients with NAFLD-HCC were the least likely to receive any form of curative treatment. Furthermore, they had worse median survival after OLT, but better is the definition of our NAFLD and non-NAFLD groups. The NAFLD group used clinical diagnoses consistent with NAFLD and/or the metabolic syndrome as done in previously published studies 6, 24, 25 in the light of the lack of specific ICD-9-CM code for NAFLD and the underdiagnosis of NAFLD in earlier years. The non-NAFLD group was defined by clinical diagnoses of HBV, HCV and ALD using available ICD-9-CM codes, but concurrent diagnosis of fatty liver could not be fully excluded
given the lack of well-defined ICD-9-CM codes for NAFLD. Recognising these limitations, exclusions of any concurrent liver disease, including viral hepatitis and all other liver diseases as outlined in our methods section, were done to ensure strict inclusion criteria of our NAFLD group.
Furthermore, clinically relevant data such as laboratory data used to derive Model for End-Stage Liver Disease score were not available, although diagnosis codes to identify hepatic decompensation were employed to reflect disease severity and hepatic function.
In conclusion, our findings show that patients with NAFLDrelated HCC continue to have low rates of curative treatment despite controlling for cardiovascular disease, cirrhosis, decompensated liver disease, metastatic HCC and large primary tumour size >5 cm. Survival after OLT was lowest among those with NAFLDrelated HCC, although favourable after hepatic resection, particularly in noncirrhotic patients. We believe this study represents the largest national cohort study to date to address NAFLD-related HCC treatment and survival, stratified by curative treatment modality and provides new evidence for hepatic resection as a viable treatment option for HCC among patients with noncirrhotic NAFLD, for whom post-resection survival may be influenced predominantly by male sex and metastatic disease rather than primary tumour size. In context of the rising prevalence of NAFLD and NAFLD-related HCC in the United States, these findings further underscore the ongoing need for investigation to improve evidence-based surveillance, diagnosis and treatment of HCC in this growing patient population.
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